Conjugated linoleic acid (CLA) has been found to exert beneficial effects on lipid profile and repress de novo fatty acid synthesis in mammary gland during lactation. However, the underlying mechanisms responsible for the antilipogenic effects of CLA have not been established. The cytosolic NADP 1 -dependent isocitrate dehydrogenase (IDH1) plays a critical role in cholesterol and fatty acid biosynthesis by providing reducing equivalents as NADPH. In previous studies, we documented that the expression of IDH1 in bovine mammary epithelium was modulated by regulators of mammary differentiation and metabolic effectors. In this study, we investigated the short-term effects of prolactin (PRL) and CLA on IDH1 expression in BME-UV bovine mammary epithelial cells. In time-course experiments, we found that the treatment with PRL for 60 and 90 min elicited a significant increase in IDH1 transcript levels. Conversely, the cotreatment of BME-UV cells with PRL plus a CLA mixture for 90 min prevented the accumulation of IDH1 mRNA induced by PRL. In addition, we found that the trans-10, cis-12 CLA, but not the cis-9, trans-11 CLA isomer, inhibited basal-and PRL-induced IDH1 mRNA expression. The inhibitory effects of the trans-10, cis-12 CLA isomer on PRL-induced IDH1 expression accumulation were confirmed by quantitative real time PCR and western-blotting analysis. We propose that the inhibitory effects of CLA on milk fat synthesis in mammary epithelial cells may derive, at least in part, from repression of IDH1 expression.
Introduction
Conjugated linoleic acid (CLA) 1 refers to a naturally occurring mixture of positional and geometric isomers of linoleic acid with conjugated double bonds produced by bacterial biohydrogenation in the ruminant gut (1) . CLA is widely found in many foods, including dairy products, meats, and certain vegetable products (2) . The cis-9, trans-11 (c9, t11) and trans-10, cis-12 (t10, c12) CLA are the major isomers in the commercially available CLA mixtures, whereas other isomers are also present at lower concentrations (3, 4) . It has been reported that exogenous CLA reduced bovine milk fat concentration and yield by inhibiting de novo fatty acid synthesis (5) and that the supplementation with equivalent doses of t10, c12 CLA reduced milk fat synthesis in lactating sheep (6) . Results from a double-blind, placebocontrolled, crossover study revealed that in humans the maternal supplementation with CLA also decreased milk fat content (7) .
Based on results of in vivo and in vitro studies, several beneficial roles of CLA in modulation of lipid metabolism have been suggested. For example, mice and growing pigs fed a CLAsupplemented diet exhibited lower body fat and increased lean body mass relative to control animals (8, 9) . The reduction of body fat content in mice elicited by CLA occurred without affecting energy intake (10) . It has also been reported that natural concentrations of the c9, t11-CLA have antiatherogenic effects in hyperlipidemic hamsters (11, 12) . In vitro studies indicated that both a commercially available mixture of CLA isomers and the t10, c12 CLA reduced the triglyceride content and induced apoptosis in differentiation cultures of murine 3T3-L1 preadipocytes (13) . Finally, it has been noted that infusing t10, c12-CLA in lactating dairy cows decreased the mRNA expression of several lipogenic genes including acetyl CoA carboxylase (ACC), fatty acid synthetase (FAS), and D-9-desaturase (14) . Despite the wealth of data documenting the antilipogenic effects of CLA both in animals and humans, the mechanisms by which CLA alters lipid metabolism are not clearly defined.
A key enzyme involved in fatty acid synthesis is the cytosolic NADP 1 -dependent isocitrate dehydrogenase (IDH1), which provides reducing equivalents in the form of NADPH. The IDH1 enzyme generates the primary source of NADPH required for de novo fatty acid synthesis in the bovine mammary gland during lactation (15, 16) . The crucial role of IDH1 in lipid metabolism has also been demonstrated by Koh et al. (17) using 3T3-L1 cells and transgenic mice overexpressing IDH1 (17) . Recently (18), we reported on the regulation of IDH1 expression in bovine mammary tissue and in an established mammary epithelial cell line. However, no information regarding the regulation of IDH1 expression by CLA is available.
Materials and Methods
Cell culture. The BME-UV bovine mammary epithelial cell line was kindly provided by Dr. Politis (University of Vermont, Burlingon, Vermont). BME-UV cells were maintained in DMEM supplemented with 10% fetal calf serum at 37°C and 5% CO 2 atmosphere and cells were routinely passaged every 6-7 d by washing with Dulbecco's PBS followed by trypsinization.
Reagents and chemicals. Bovine prolactin (PRL) was obtained from the National Institute of Diabetes and Digestive and Kidney Diseases National Hormone and Pituitary Program (isolated from bovine pituitary gland, 90-95% monomeric, lot no. AF7170E). DMEM was obtained from Sigma Chemical, fetal calf serum was purchased from Hyclone Laboratories. The mixture of CLA isomers (CLAmix) was obtained from Sigma and consisted of t9, c11 and c9, t11 (50%), t10, c12 (40%), and c10, t12 (10%). Purified (;98% purity) c9, t11-and t10, c12-CLA isomers were obtained from Matreya. TriReagent was purchased from Molecular Research Center. Random hexamer primers, Moloney murine leukemia virus reverse transcriptase, and RNase inhibitor were purchased from Life Technologies. Reverse transcription buffer was obtained from Ambion. Vent DNA polymerase was purchased from New England Biolabs. The antibody against the mammalian IDH1 was kindly provided by Dr. McAlister-Henn (University of Texas Health Science Center, San Antonio, TX).
Semiquantitative RT-PCR. Optimization of conditions for amplification of IDH1 are described elsewhere (18) . Briefly, oligonucleotides used to amplify the IDH1 fragment (384 bp) were (forward) 5#-GTCTGTGGTAGAGATGCAAGG-3# and (reverse) 5#-CCATAAG-CATGACGACCTATG-3#. PCRs were performed using Vent DNA polymerase. The authenticity of the IDH1 product was confirmed by direct sequencing and BLAST analysis against deposited sequences in the Genbank database. Ribosomal 18S RNA was also amplified to control for PCR conditions and equal loading. Relative levels of IDH1 were estimated by Kodak 1D Image (Eastman Kodak) analysis and corrected for expression of the control RNA.
Real-time PCR. cDNA was prepared by reverse transcription of sample RNA using the Bio-Rad iScript cDNA kit (Bio-Rad Laboratories) in a reaction volume of 40 mL. DNA standards were prepared from PCR amplicons purified using the QIAquick PCR purification kit (Qiagen). Product concentrations and the quantity of cDNA in unknown samples were determined as previously described (19) . Real-time PCR was performed using the Bio-Rad MyiQ Real-Time Single Color PCR Detection system in Bio-Rad 96-well plates in a 25-mL volume. The PCR program was as follows: 95°C initial denaturation for 3 min, followed by 45 cycles of 94°C for 15 s, 57°C for 30 s, 72°C for 30 s, then 95°C for 1 min, 55°C for 1 min, and holding at 4°C. A 1-mL sample cDNA or standard was added to 24 mL of reaction mix in the wells. Oligonucleotides used to amplify IDH1 (149 bp) were (forward) 5#-CAAGGCGGGTCTGTGG-TAG-3# and (reverse) 5#-TGGTCGTTGGTGGCATCG-3#.
Western blotting. Western-blotting analysis for IDH1 was performed as described previously (18) . Immunoblotting was carried out with rabbit polyclonal antibody against IDH1. Normalization of western blots was confirmed by incubating immunoblots with b-actin antibody-1 (Oncogene Research Products). The immunocomplexes were detected by enhanced chemiluminescence (Amersham).
Data analysis. Fold-changes in expression of IDH1 mRNA are presented as means 6 SEM. Significance (P , 0.05) of the differences between means was determined by t test or one-way ANOVA followed by Fisher's protected least significant difference test.
Results
In a recent study (18) , we found that the long-term treatment (72 h) with PRL stimulates the expression of IDH1. To evaluate the short-term effects of PRL on IDH1 expression, BME-UV cells were cultured in basal medium (DMEM) or DMEM supplemented with PRL (2.0 mg/L) for 15, 30, 60, and 90 min. Compared with the basal expression measured in cells cultured in DMEM, IDH1 mRNA levels increased (P , 0.05) 94 and 122% in cells treated with PRL, respectively, for 60 and 90 min (Fig. 1) . Conversely, PRL had no effect at earlier time points (15 and 30 min).
Because CLA has been shown to repress milk fat synthesis both in animals and humans (5,7), we investigated whether or not CLA influenced basal and PRL-induced IDH1 expression. We treated BME-UV cells with 2.0 mg/L PRL, 20 or 40 mmol/L CLAmix, or a combination of 2.0 mg/L PRL plus 20 or 40 mmol/L CLAmix for 90 min. For these experiments, we used a CLAmix containing t9, c11 and c9, t11 (50%), t10, c12 (40%), and c10, t12 (10%) CLA isomers. Treatment with 40 mmol/L CLAmix tended to reduce (P , 0.10) basal IDH1 mRNA levels, whereas the cotreatment with the CLAmix plus PRL completely abolished the stimulatory effects of PRL ( Fig. 2A,B) . These cumulative data suggest that CLA prevents the rapid PRL-induced stimulation of IDH1 mRNA expression.
Because distinct biological effects have been documented for various CLA isomers (20), we tested whether or not c9, t11 CLA and t10, c12 CLA differentially regulated IDH1 expression. We cultured BME-UV cells for 90 min in DMEM, DMEM supplemented with 40 mmol/L c9, t11 CLA or t10, c12 CLA in the presence or absence of 2.0 mg/L PRL and measured IDH1 mRNA levels. We observed that the treatment with the t10, c12 CLA isomer decreased (P , 0.05) both basal and PRL-induced IDH1 mRNA expression. In contrast, the c9, t11 CLA isomer had no significant effects on basal and PRL-stimulated IDH1 mRNA levels. The CLAmix did not influence basal IDH1 expression, but it abrogated the stimulatory effects of PRL on IDH1 transcripts (Fig. 3A,B) . The results of real-time PCR measurements confirmed that the cotreatment with the t10, c12 CLA, but not the c9, t11 CLA isomer, reduced PRL-induced IDH1 mRNA expression (Fig. 3C) . Next, we investigated by western blotting the effects of the CLAmix, c9, t11 CLA, and t10, c12 CLA isomer on IDH1 protein levels. The cotreatments with the CLAmix and the t10, c12 CLA isomer reduced PRLinduced IDH1 protein expression (Fig. 4) . Taken together, these results suggest that PRL stimulates a rapid increase in IDH1 mRNA and protein, whereas these effects are abrogated by selected CLA isomers.
Discussion
In recent years, a key role for IDH1 in lipid metabolism has been proposed (17) . IDH1 catalyzes the decarboxylation of isocitrate in the cytosol and utilizes NADP 1 as a cofactor to generate the reducing equivalent NADPH, which is required for fatty acid and cholesterol synthesis (21, 22) . It has been documented that in rat liver the enzymatic activity of IDH1 was 16-and 18-fold higher, respectively, than that of the glucose-6-phosphate and malate dehydrogenase (23) , which are 2 enzymes that generate NADPH in the cytosol. Results of a study with normal subjects and obese patients have shown that IDH1 participates in fatty acid synthesis directly through the backward pathway of the Krebs cycle (24). Koh et al. (17) reported that overexpression of IDH1 by stable transfection of IDH1 cDNA stimulates adipogenesis of 3T3-L1 adipocytes and that transgenic mice overexpressing IDH1 exhibit fatty liver, hyperlipidemia, and obesity (17) .
Because IDH1 may play an important role in lipid metabolism, it is important to know how the IDH1 gene is regulated. The enzymatic activity of IDH1 has been shown to increase dramatically in early lactation in bovine mammary gland (16) . It has been suggested that IDH1 is the primary source of NADPH for de novo fatty acid synthesis in the bovine mammary gland due to the fact that the activities of other NADPH-producing pathways are much lower (15) . We have previously reported that treatment with PRL for 72 h elicited a significant increase in IDH1 expression in a bovine mammary epithelial cell line (BME-UV) (18) . In the present study, we examined the shortterm effects of PRL and found that it stimulated within 60 min IDH1 mRNA and protein expression. A possible interpretation of these cumulative data is that PRL may stimulate IDH1 expression through 2 not mutually exclusive mechanisms. The long-term effects of PRL may be achieved through stimulation of biochemical events that accompany cell differentiation (25) , whereas the short-term effects of PRL on IDH1 expression may be due to direct activation of signaling pathways (26) . The current study and our published data (18) suggest that both IDH1 transcript and protein levels can be modulated by hormones in BME-UV cells. These findings are consistent with previous reports by other groups (27) documenting that IDH1 mRNA levels increased 13-fold during the gonadotropin-induced development of the immature rat ovary. However, Koh et al. (17) reported that IDH1 is regulated post-transcriptionally without changes in mRNA levels in differentiating 3T3-L1 cells (17) . Therefore, it is possible that the expression of IDH1 may be regulated both at the transcriptional and post-transcriptional level depending on tissue type and stage of development.
The ACC and FAS are 2 rate-limiting enzymes for fatty acid synthesis in bovine mammary tissue (28) . ACC converts acetylCoA to malonyl-CoA. The condensation of acetyl-CoA and malonyl-CoA and the subsequent elongation of the fatty acid chain are catalyzed by the enzyme complex FAS. Interestingly, previous studies have shown that PRL stimulated the enzymatic activity of ACC and FAS in mammary gland explants (29) and activated promoter activity of the ACC gene in bovine mammary epithelial cells (30) . The stimulation of IDH1 expression by PRL documented by our studies may represent an additional mechanism that regulates fatty acid synthesis by affecting the supply of reducing equivalents NADPH required by the reductase component of the FAS enzyme. Investigations of the temporal interrelations between ACC, FAS, and IDH1 in response to hormonal stimuli and metabolic effectors are necessary to fully understand the underlying mechanisms that regulate fatty acid synthesis in the lactating mammary gland.
CLA has been shown to inhibit milk fat synthesis (5) and modulate lipid metabolism (31) (32) (33) in several species. However, the mechanisms through which CLA exerts its antilipogenic effects have not been clearly elucidated. Although inhibitory effects of CLA on mRNA expression of ACC and FAS have been documented in previous studies (14, 34) , no information is available regarding the effects of CLA on regulation of IDH1 expression. We report for the first time, to our knowledge, that CLA repressed in bovine mammary epithelial cells the stimulatory effects of PRL on IDH1 mRNA and protein expression. Our interpretation of these results is that repression of IDH1 expression may be one of the mechanisms that mediate the negative effects of CLA on de novo fatty acid synthesis in the lactating mammary gland. As previously reported (18), IDH1 expression is likely regulated by other fatty acids and metabolic effectors. However, of the CLA isomers tested in this study, only the t10, c12 CLA exerted a repressive effect on PRL-induced IDH-1 mRNA and protein. Therefore, the effects of t10, c12CLA on IDH1 expression are likely specific and in agreement with previous findings by our group (35, 36) and other investigators (34, 37) documenting that the t10, c12 CLA isomer is more biologically active compared with the c9, t11 CLA.
In summary, we report that the peptide hormone PRL rapidly enhances IDH1 mRNA and protein expression in BME-UV bovine mammary epithelial cells. The stimulatory effects of PRL on IDH1 expression are counteracted by the cotreatment with a mixture of CLA or the t10, c12 CLA isomer, but not c9, t11 CLA.
The molecular mechanisms of CLA action on IDH1 gene expression require further investigation.
